


イプリフラボン（日本薬局方記載条件）
Ipriflavone (The Japanese Pharmacopoeia)

F170222A


(A) Assay : Standard solution*

(60 µg/mL Ipriflavone, 1 µL/mL Di-*n*-butyl phthalate)




	System suitability requirement	Result
Resolution (1, 2)	≥ 3	10.5
Relative standard deviation of the peak area ratio of 1 to 2 (n=6)	≤ 1.0%	0.15%

1



Ipriflavone


2



Di-*n*-butyl phthalate (I.S.)

(B) Related substance : Standard solution*

(0.6 µg/mL Ipriflavone)



	System suitability requirement	Result
Theoretical plate number (Ipriflavone)	≥ 2,000	4,700
Tailing factor (Ipriflavone)	≤ 1.5	0.88
Relative standard deviation of the peak area (n=6) (Ipriflavone)	≤ 2.0%	1.31
Peak area ratio of test solution for required detectability (0.06 µg/mL) to standard solution (Ipriflavone)	7-13%	9.9%

Column : YMC-Triart C8 (5 µm, 12 nm)
150 X 4.0 mm I.D.

Eluent : acetonitrile/water (60/40)

Flow rate : 1.0 mL/min (*adjust the flow rate so that the retention time of Ipriflavone is about 6 min*)

Temperature : 25°C

Detection : UV at 280 nm

Injection : 20 µL

(The Japanese Pharmacopoeia 17th; Assay, Related substances)

* All standard solutions were prepared from Ipriflavone supplied as a reagent for laboratory use.